- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05375799
Clinical and Electronic Record for Patients With COVID-19 Treated With the Assisted Breathing Helmet - ELMO in Ceará (COVID-19)
Continuous positive airway pressure (CPAP) with a helmet-like interface has been described as a safe strategy, with minimal contamination of the environment, improving the oxygenation of patients with acute respiratory failure (ARF) by COVID-19, avoiding intubation in more than half of the cases. ELMOcpap, developed in Ceará, was a great ally in the treatment of these cases during the pandemic in the state. It is estimated that among public and private services, more than 1.400 ELMOs have been applied to patients with COVID-19. However, the determining factors of the success and failure of its use in the different institutions in which it has been applied are still unknown. Therefore, it is necessary to survey all data associated with the use of the device.
Objectives: 1. To describe the effects of ELMO in the treatment of patients with hypoxemic respiratory failure due to COVID-19 in a database, in a systematic and standardized way, on clinical history, efficacy, safety, modes, duration of use, the occurrence of adverse events and early predictors of failure. 2. Determine the intubation rate of patients with COVID-19 hypoxemic respiratory failure who used the ELMO. 3. Identify the mortality rate of patients with hypoxemic respiratory failure due to COVID-19 who used the ELMO.
Methods: This is a retrospective, multicenter, observational, cohort study of recorded data from patients with COVID-19 hypoxemic respiratory failure who were treated with the ELMO. An online electronic form will be developed with REDCap, where the responsible investigator of each institution will be responsible for filling in the participants' data, ensuring adherence to the protocol and analysis will be carried out of the data of the patients of the participating services of the research that used the ELMO as treatment.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
An online electronic form will be developed with REDCap, where the responsible investigator of each institution will be responsible for filling in the participants' data, ensuring adherence to the protocol.
The researchers involved will undergo qualified training and will receive a video, showing step-by-step how REDCap works, so that there are no doubts about the data collection process and to ensure the standardization of the collection protocol.
An explanation of the nature and objectives of the study will be presented to the research subjects, as well as its importance to society, health professionals and researchers.
The investigators will visit the hospital at least five times a week in the morning, afternoon and/or night shifts, for data collection, with monitoring and collection of outcomes being performed daily.
Type d'étude
Inscription (Anticipé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Luiza G Frota, PHD
- Numéro de téléphone: 8499 558533668499
- E-mail: gabigomes1@hotmail.com
Lieux d'étude
-
-
Ceara
-
Fortaleza, Ceara, Brésil, 60135-285
- Recrutement
- Hospital Leonardo Da Vinci
-
Contact:
- Marcelo A Holanda, PHD
- Numéro de téléphone: +558531011398
- E-mail: cep@esp.ce.gov.br
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Patients with COVID-19, confirmed by laboratory detection of SARS-CoV-2 RNA, who used the Assisted Breathing Helmet - ELMO in referral hospitals in Fortaleza, Brazil.
Data will be collected retrospectively from adult patients admitted to the ICU and wards during the COVID-19 pandemic in Fortaleza.
An online electronic form will be developed with REDCap, where the responsible investigator of each institution will be responsible for filling in the participants' data, ensuring adherence to the protocol.
La description
Inclusion Criteria:
- Data from adult patients diagnosed with COVID-19 described in medical records by laboratory detection of RNA of SARS-CoV-2, who used the Assisted Breathing Helmet - ELMO, will be recruited.
Exclusion Criteria:
- Illegible medical records or forms or with incomplete data that make it impossible to collect data will be excluded.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
---|---|
COVID-19 in use of ELMO
This is an observational study, so there are no interventions.
Data will be recruited from adult patients diagnosed with COVID-19, described in medical records, by laboratory detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA, who used the Assisted Breathing Helmet - ELMO.
|
This is an observational study, so there are no interventions. Data will be recruited from adult patients diagnosed with COVID-19, described in medical records, by laboratory detection of SARS-CoV-2 RNA, who used the Assisted Breathing Helmet - ELMO. All the following predictor variables will be collected: demographic and anthropometric data; clinical characteristics of patients (comorbidities, date of onset of symptoms and initial symptoms, hospital admission, laboratory tests, chest X-ray tests, need for intubation or ICU admission); start date of ELMO use, blood gas analysis before and after the first application of ELMO and data related to its use (number of applications, number of days of therapy, total time of therapy, as well as reasons for the interruption and adverse effects ). |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Risk factors for intubation
Délai: up to 60 days
|
To evaluate the risk factors for intubation of patients with hypoxemic ARF due to COVID-19 who used the Assisted Breathing Helmet - ELMO.
|
up to 60 days
|
Risk factors for death
Délai: up to 90 days
|
To evaluate the risk factors for death of patients with hypoxemic ARF due to COVID-19 who used the Assisted Breathing Helmet - ELMO.
|
up to 90 days
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Time to start ELMO therapy
Délai: up to 28 days
|
Time to start using the Assisted Breathing Helmet - ELMO
|
up to 28 days
|
Total time of use ELMO therapy
Délai: up to 60 days
|
Total time of use of the Assisted Breathing Helmet - ELMO
|
up to 60 days
|
Adverse events of ELMO
Délai: up to 60 days
|
Adverse events with the use of the Assisted Breathing Helmet - ELMO
|
up to 60 days
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Marcelo A Holanda, PHD, Escola Saude Publica
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 4.833.400
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur COVID-19 [feminine]
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkPas encore de recrutementSyndrome post-COVID-19 | Longue COVID | Longue Covid19 | État post-COVID-19 | Syndrome post-COVID | Condition post-COVID-19, non précisée | État post-COVIDPays-Bas
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlComplétéSéquelles post-aiguës de la COVID-19 | État post-COVID-19 | Long-COVID | Syndrome chronique du COVID-19Italie
-
Indonesia UniversityRecrutementSyndrome post-COVID-19 | Longue COVID | État post-COVID-19 | Syndrome post-COVID | Longue COVID-19Indonésie
-
Yang I. PachankisActif, ne recrute pasInfection respiratoire COVID-19 | Syndrome de stress COVID-19 | Effet indésirable du vaccin COVID-19 | Thromboembolie associée au COVID-19 | Syndrome de soins post-intensifs COVID-19 | AVC associé à la COVID-19Chine
-
Massachusetts General HospitalRecrutementSyndrome post-aigu COVID-19 | Longue COVID | Séquelles post-aiguës de la COVID-19 | Longue COVID-19États-Unis
-
Sheba Medical CenterInconnue
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecrutementCOVID-19 Pneumonie | Infection respiratoire COVID-19 | Pandémie de covid-19 | COVID-19 Syndrome de Détresse Respiratoire Aiguë | COVID-19-Pneumonie associée | Coagulopathie associée au COVID 19 | COVID-19 (maladie à coronavirus 2019) | Thromboembolie associée au COVID-19Grèce
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecrutementPandémie de covid-19 | Vaccins contre le covid-19 | Maladie à virus COVID-19Indonésie
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital; Yulin No.2 Hospital et autres collaborateursRecrutementCOVID-19 [feminine] | Syndrome post-COVID-19 | COVID-19 post-aiguë | COVID-19 aiguëChine
-
Jonathann Kuo, MDActif, ne recrute pasInfection par le SRAS-CoV2 | Syndrome post-COVID-19 | Dysautonomie | Syndrome post-aigu COVID-19 | Longue COVID | Longue Covid19 | COVID-19 récurrent | COVID-19 post-aiguë | Infection COVID-19 post-aiguë | Séquelles post-aiguës de la COVID-19 | Dysautonomie comme trouble | Dysautonomie Syndrome d'hypotension... et d'autres conditionsÉtats-Unis
Essais cliniques sur Clinical Observation
-
Beth Israel Deaconess Medical CenterBrigham and Women's Hospital; Clinical Innovations, LLCRecrutementComplications de la césarienne | Obésité morbideÉtats-Unis
-
DascenaNational Institute on Alcohol Abuse and Alcoholism (NIAAA); Baystate Health; Cape Regional Medical Center et autres collaborateursRecrutementÉtat septique | Choc septique | Septicémie sévèreÉtats-Unis
-
Swiss Group for Clinical Cancer ResearchImmunophotonics, Inc.RecrutementTumeurs solides avancéesSuisse
-
University of NottinghamEnhanced Recovery After Surgery Group (part of ESPEN)Complété
-
St. Louis UniversityTriumph PharmaceuticalsComplétéParodontite | GingiviteÉtats-Unis
-
Centre for Addiction and Mental HealthUniversity Health Network, TorontoComplétéTrouble dépressif majeurCanada
-
Womack Army Medical CenterUnited States Department of Defense; Walter Reed National Military Medical...RecrutementBlessures musculosquelettiquesÉtats-Unis
-
Ospedale San Giovanni BellinzonaSwiss Heart FoundationComplétéInfarctus aigu du myocarde | Cardiomyopathie de Takotsubo | Syndrome X cardiaqueSuisse
-
Major Extremity Trauma Research ConsortiumComplété
-
Johnson & Johnson Consumer Inc. (J&JCI)Complété